Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Analysts at SunTrust Banks boosted their Q4 2017 EPS estimates for shares of Catalyst Pharmaceuticals in a research note issued to investors on Thursday. SunTrust Banks analyst E. Nash now expects that the biopharmaceutical company will post earnings of ($0.05) per share for the quarter, up from their prior forecast of ($0.06). SunTrust Banks also issued estimates for Catalyst Pharmaceuticals’ FY2018 earnings at ($0.30) EPS, FY2019 earnings at ($0.23) EPS, FY2020 earnings at $0.05 EPS and FY2021 earnings at $0.57 EPS.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01.

ILLEGAL ACTIVITY WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/08/14/catalyst-pharmaceuticals-inc-to-post-q4-2017-earnings-of-0-05-per-share-suntrust-banks-forecasts-nasdaqcprx.html.

Other equities analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research report on Monday, May 22nd. Roth Capital set a $5.00 target price on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday. Finally, Piper Jaffray Companies set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 7th.

Shares of Catalyst Pharmaceuticals (CPRX) opened at 2.72 on Monday. Catalyst Pharmaceuticals has a 52 week low of $0.73 and a 52 week high of $3.20. The firm’s market cap is $229.99 million. The firm has a 50-day moving average of $2.88 and a 200 day moving average of $1.98.

Several hedge funds have recently made changes to their positions in the stock. OxFORD Asset Management LLP raised its position in Catalyst Pharmaceuticals by 46.2% in the second quarter. OxFORD Asset Management LLP now owns 86,168 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 27,228 shares in the last quarter. Virtu KCG Holdings LLC acquired a new stake in Catalyst Pharmaceuticals during the second quarter valued at approximately $237,000. FMR LLC acquired a new stake in Catalyst Pharmaceuticals during the second quarter valued at approximately $828,000. Vanguard Group Inc. raised its stake in Catalyst Pharmaceuticals by 11.3% in the second quarter. Vanguard Group Inc. now owns 3,348,549 shares of the biopharmaceutical company’s stock valued at $9,242,000 after buying an additional 340,614 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Catalyst Pharmaceuticals by 620.9% in the second quarter. Northern Trust Corp now owns 802,566 shares of the biopharmaceutical company’s stock valued at $2,215,000 after buying an additional 691,238 shares during the last quarter. Hedge funds and other institutional investors own 30.28% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.